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Abstract: Consumption of cruciferous vegetables is associated with a decreased risk of developing prostate cancer.
Antineoplastic effects of cruciferous vegetables are attributable to bioactive indoles, most prominently, 3, 3’-diindolylmethane (DIM). In addition to effects on proliferation and apoptosis, DIM acts as an antiandrogen in prostate
cancer cell lines. This study characterized the effects of prostatic DIM on the androgen receptor (AR) in patients with
prostate cancer. Men with localized prostate cancer were treated with a specially formulated DIM capsule designed
for enhanced bioavailability (BR-DIM) at a dose of 225 mg orally twice daily for a minimum of 14 days. DIM levels
and AR activity were assessed at the time of prostatectomy. Out of 28 evaluable patients, 26 (93%) had detectable
prostatic DIM levels, with a mean concentration of 14.2 ng/gm. The mean DIM plasma level on BR-DIM therapy
was 9.0 ng/mL; levels were undetectable at baseline and in follow-up samples. AR localization in the prostate was
assessed with immunohistochemistry. After BR-DIM therapy, 96% of patients exhibited exclusion of the AR from
the cell nucleus. In contrast, in prostate biopsy samples obtained prior to BR-DIM therapy, no patient exhibited AR
nuclear exclusion. Declines in PSA were observed in a majority of patients (71%). Compliance was excellent and
toxicity was minimal. In summary, BR-DIM treatment resulted in reliable prostatic DIM levels and anti-androgenic
biologic effects at well tolerated doses. These results support further investigation of BR-DIM as a chemopreventive
and therapeutic agent in prostate cancer.
Keywords: 3, 3’-Diindolylmethane, BR-DIM, prostate cancer, cruciferous vegetables, anti-androgen

Introduction
Prostate cancer is the most common cancer
diagnosis and the second leading cause of cancer death for men in the United States [1].
Dietary factors have emerged as one potential
modifiable prostate cancer risk factor [2]. In
particular, consumption of cruciferous vegetables, such as broccoli, Brussels sprouts, and
cauliflower, is associated with decreased cancer incidence [3, 4]. High dietary intake of cruciferous vegetables has been associated with
reduced prostate cancer risk [5] and less aggressive disease at presentation [6]. Two major
bioactive compounds in cruciferous vegetables
are indole-3-carbinol (I3C) and 3, 3’-diindolylmethane (DIM). I3C is converted to its dimeric
derivative, DIM, during cooking. When added in
vitro to cell culture media, I3C spontaneously
dimerizes, forming DIM in a quantitative and

time-dependent fashion [7]. These two indoles
have multiple potentially therapeutic effects
when studied in vitro. I3C and DIM administration have anti-proliferative and pro-apoptotic
effects in several tumor cell lines [8-10]. I3C
and DIM inhibit cell growth, induce G1 cell-cycle
arrest, and promote apoptosis in androgenindependent and androgen-dependent prostate cancer cells [11-16].
Diverse molecular mechanisms appear to be
responsible for these biological effects, but an
intriguing finding in prostate cancer is that DIM
functions as an androgen receptor (AR) antagonist [11]. DIM down-regulates expression of the
AR [17] and prevents AR translocation to the
nucleus [11]. As a consequence, DIM treatment
leads to decreased transcription of androgen
receptor target genes such as PSA. Furthermore,
DIM exhibits no AR agonist activity. When evalu-
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ated in pre-clinical models, DIM has been shown to have therapeutic effect in flank and
metastatic murine prostate cancer models [14,
17].
Nutritional grade absorption-enhanced DIM
(BR-DIM) is a dietary supplement that contains
pharmaceutically pure DIM, microdispersed in
spray-dried starch particles. Previous human
studies with BR-DIM have reported minimal toxicity [18-20]. We have previously completed a
phase I clinical trial of BR-DIM in patients with non-metastatic, hormone-refractory prostate cancer with rising serum PSA [19]. The recommended phase II dose based on toxicity and
pharmacokinetic data was 225 mg orally twice
daily. Armed with the appropriate dose and
schedule, we proceeded with a phase II clinical
trial in patients with prostate cancer. BR-DIM
was administered to patients prior to radical
prostatectomy (RP) with the primary objective
of measuring DIM levels in prostate tissue and
in plasma. We hypothesized that BR-DIM administration in prostate cancer patients would
lead to the accumulation of DIM in the prostate
tissue. Further, this study allowed us to test
whether prostatic DIM would act as an antiandrogen in a clinical setting.
Material and methods
Study design and conduct
The review boards of both participating institutions (Wayne State University and Henry Ford
Health System) approved the study. The study
was conducted according to the provisions of
the Declaration of Helsinki and the Good Clinical Practice Guidelines of the International Conference on Harmonization. All patients provided
written informed consent prior to participation
in the study.
The study was designed and the protocol was
written by the senior academic authors. The
first draft of the manuscript was written by the
first author, and the manuscript was then completed and approved by all the authors. All the
authors were responsible for writing the manuscript and for the decision to submit the manuscript for publication, and all the authors assume responsibility for the completeness and
integrity of the data and the fidelity of the study
to the protocol and analysis plan (see supplemental information for full protocol). All the
authors or authors’ institutions had agreeme167

nts with the lead investigational site regarding
confidentiality of the data. No one who is not an
author contributed to the writing of the manuscript. The protocol was registered on the NIH
clinical trials database prior to the enrollment
of any patients (http://clinicaltrials.gov/show/
NCT00888654).
Study participants
Patients were eligible for enrollment if they had
a histologically or cytologically confirmed diagnosis of treatment-naïve prostate cancer, with
clinical T1 or T2 disease, and suitable for prostatectomy according to the clinical judgment
of their surgeon. Patients were required to have adequate hematologic, hepatic, and renal
function, with an ECOG performance status of
≤ 2. Patients were not permitted to take any
other antineoplastic agents, micronutrient supplements or dietary soy products while enrolled on study. Concomitant treatment with known P450 inducers and inhibitors (e.g. carbamazepine, clarithromycin, fluconazole, fosphenytoin, itraconazole, ketoconazole, phenobarbital, phenytoin, rifabutin, and rifampin) with potential to interfere with the metabolism of
BR-DIM was not allowed. In addition, no androgen deprivation therapy, including the use of
5-alpha-reductase inhibitors, was allowed on
study. Patients with serious and uncontrolled
acute or chronic medical or psychiatric conditions were not eligible. A complete list of inclusion and exclusion criteria is provided in the
protocol (Supplementary Information).
Study treatment and evaluation
Prior to planned prostatectomy, eligible and
consenting subjects were prescribed BR-DIM
(BioResponse, LLC, Boulder, CO) at a dose of
225 mg orally twice daily for a minimum of 14
days and up to 72 days (depending on surgical
scheduling). Each 75 mg BR-DIM capsule was
produced following Good Manufacturing Practice (GMP) regulations, which include in-process testing for DIM and post-production assay
for DIM content using an HPLC method performed by independent analytic laboratory. Patients were instructed to take 3 tablets twice
daily with 8 ounces of water, with or without
food. The last dose of study drug was to be
taken on the evening before surgery. If surgery
was delayed beyond 72 days from the BR-DIM
treatment start date, BR-DIM was discontinued. Otherwise, BR-DIM treatment continued
Am J Transl Res 2016;8(1):166-176
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until either surgery or one of the following events: disease progression, intercurrent illness
which precluded further treatment, unacceptable toxicity (defined as CTCAE version 3.0
grade 3 or higher toxicity), or patient or investigator request. No dose modification was allowed. Eligible patients were evaluable if they
had at least 14 days of BR-DIM treatment.
Eligible, evaluable patients were compliant if
they took at least 80% of the first 14 days of
intended BR-DIM treatment based on pill count.
Pharmacokinetic and pharmacodynamic
measures
Blood samples for DIM levels were collected
before starting BR-DIM treatment, immediately
prior to surgery, and during routine follow-up
within the first 24 months after prostatectomy.
Within 1 hour of collection in heparin anticoagulant tubes, blood samples were centrifuged at
25°C at 3000 rpm for 10 minutes. Plasma was
immediately transferred to cryogenic tubes in
two aliquots and kept at -80°C until analysis.
DIM concentration in human plasma was measured using a validated high-performance liquid chromatographic method with tandem mass spectrometric (LC-MS/MS) detection as previously described [19]. DIM levels were also
measured in prostate tissue. Approximately
250-500 mg of fresh tissue specimen from the
prostatectomy (benign prostate) was collected
and stored at -80°C until analysis. DIM concentration in the prostate was determined using a
validated LC-MS/MS method. Serum PSA and
testosterone levels were taken at the same
time as DIM samples (pre-treatment, pre-surgery, and post-surgery) and processed in the
clinical laboratory according to usual procedures.
Immunohistochemistry
Formalin-fixed paraffin-embedded tissues were processed for immunohistochemical analysis as follows. Deparaffinized sections were
stained manually using the avidin-biotin-complex technique. Four micron tissue sections
were cut from the selected tumor blocks on
charged slides and stained for immunohistochemical analysis using specific antibodies for
Androgen Receptor (Monoclonal Mouse AntiHuman Clone AR441, Dako Carpinteria, CA; Code # M3562) using the polymer based detection system. Standard staining protocols according to the laboratory manual and the manufac168

turer’s suggested specimen preparation and
staining conditions were used in the Autostainer
(Dako Link 48). All reagents used in the staining
process on the autostainer were supplied in
EnVision FLEX+, Mouse, High pH, (Link) kit
(Dako code #K8002). The protocol was then
optimized for antigen retrieval, antibody dilution and incubation conditions. A known positive tissue was stained with each investigative
case study. Briefly, after deparaffinizing and
hydrating to phosphate-buffered saline buffer
(pH 7.4), the sections were pretreated with
hydrogen peroxide (3%) for 5 minutes to remove
endogenous peroxidase. Primary antibody was
then applied, AR 1:75 for 20 minutes, followed
by washing and incubation with FLEX+ Mouse
(Linker) for 15 minutes. After buffer rinse it was
incubated with FLEX/HRP for 20 minutes. Subsequent buffer rinse was followed by FLEX+
DAB+ Substrate- Chromogen for 10 minutes
and counterstained with Mayer hematoxylin followed by dehydration and mounting. Immunostained samples were reviewed by a genitourinary pathologist who evaluated staining intensity and percent positively-stained cells. The AR
staining score was the product of these two
numbers.
Statistical methods
The study design was a 1-stage, 1-sample
Phase 2 clinical trial, enrolling patients from 2
institutions. The primary objective was to measure the level of DIM in prostate tissue after
treatment of prostate cancer patients with oral
BR-DIM at 225 mg twice daily for a minimum of
14 days. The primary statistical endpoint was
the mean level of DIM in prostate tissue after
treatment with BR-DIM. It was desired to estimate the mean level of DIM in prostate tissue
after treatment with BR-DIM to within 1/3 of a
standard deviation (SD) unit, with 90% confidence. This level of precision in the estimation
of the mean DIM level in post-treatment prostate tissue required N=27 patients (as determined via PASS 2011 software). These 27
patients were to be eligible, evaluable, and
compliant (as defined above).
Standard descriptive statistics were used to
summarize demographic and clinical variables,
as well as the plasma and prostate tissue DIM
levels. Point and 90% confidence interval (CI)
estimates of the mean plasma and prostate tissue DIM levels were calculated. Due to substantial non-normality in the distributions of
Am J Transl Res 2016;8(1):166-176
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Table 1. Patient characteristics
Characteristic
Age in years-Median (range)
Race-N (%)

Performance status-N (%)
Pre-treatment PSA (ng/mL)-Median (range)
Testosterone (ng/mL)-Median (range)
Gleason sum from biopsy-N (%)

European American
African American
Middle Eastern
Other
ECOG 0

Clinical T stage-N (%)

Clinical N stage-N (%)
Gleason sum from surgical specimen-N (%)

Pathologic T stage-N (%)

Pathologic N stage-N (%)

prostate tissue DIM level, plasma DIM level,
and length of BR-DIM treatment, nonparametric methods of statistical analysis were used,
including Spearman rank correlation coefficients. To explore the relationship of prostate tissue DIM level to plasma DIM level we used a
nonparametric regression approach. We fit a
locally estimated scatterplot smoother (LOESS)
curve to that bivariate relationship using the
LOESS procedure in SAS 9.3 software. A LOESS
curve was also fit to the bivariate relationship
of prostate tissue DIM level and length of
BR-DIM treatment. The default smoothing
parameter (percent of the total observations
used in each smoothing neighborhood) was
used in the LOESS procedure. These nonparametric LOESS curves better described the nonlinear character of those two relationships.
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6
7
≥8
T1c
T2a
T2b
T2c
N0
NX
6
7
≥8
unknown
T2a
T2c
T3a
T3b
TX
N0
NX

Eligible patients
N=40
58 (40-76)
22 (55%)
16 (40%)
1 (3%)
1 (3%)
40 (100%)
6.4 (2.1-29.4)
301 (77-608)
17 (44%)
21 (53%)
2 (5%)
30 (75%)
5 (13%)
3 (8%)
2 (5%)
11 (28%)
29 (73%)
11 (28%)
26 (65%)
2 (5%)
1 (3%)
2 (5%)
23 (58%)
10 (25%)
4 (10%)
1 (3%)
33 (85%)
7 (18%)

Evaluable patients
N=28
59 (50-73)
16 (57%)
11 (39%)
0 (0%)
1 (4%)
28 (100%)
6.4 (2.1-20.5)
292 (77-557)
11 (39%)
16 (57%)
1 (4%)
20 (71%)
3 (11%)
3 (11%)
2 (7%)
8 (29%)
20 (71%)
7 (25%)
20 (71 %)
1 (4%)
0 (0%)
1 (4%)
16 (57%)
8 (29%)
3 (11%)
0 (0%)
24 (86%)
4 (14%)

Results
Patient characteristics
A total of 41 prostate cancer patients with
plans for prostatectomy were recruited from
two institutions. One patient was deemed ineligible due to a disallowed concomitant medication yielding a total of 40 eligible patients.
Patient recruitment was comparable between
the two institutions (23 vs. 17 eligible patients).
Baseline characteristics of the 40 eligible patients are presented in Table 1. The median
age was 58 years (range, 40-76). The majority
of patients were Caucasian (55%) and 40% of
patients were African American. The significant
African American population reflects the demographics of prostate cancer patients at the two
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Figure 1. Patient disposition. Out of 41 patients who enrolled, 36 patients started protocol therapy. A total of 28
patients were evaluable for the primary endpoint of DIM levels in the prostate.

institutions. All enrolled patients had excellent
performance status (ECOG 0). The median pretreatment PSA was 6.4 ng/mL (range, 2.1-29.4
ng/mL). The median baseline testosterone level was 301 ng/mL (range, 77-608). Nearly all
patients (95%) had Gleason sum of 6 or 7 on
pre-prostatectomy biopsy. Seventy-five percent
of patients had clinical stage T1c prostate cancer; no patients had clinically apparent lymph
node metastases.
Surgical findings are reported for the 39 patients for whom data was available (Table 1). At
the time of resection, most patients were found
to have Gleason 6 or 7 disease (28% and 67%,
respectively). Disease was confined to the prostate (pT2) in 64% of patients. Extraprostatic
extension or seminal vesicle invasion (pT3) was
seen in 14 patients (36%).
Treatment and compliance
Eligible patients were instructed to take 225
mg (3 × 75 mg capsules) of BR-DIM twice daily
until the evening before planned prostatectomy. The median length of treatment on BR-DIM
was 19 days (range 4-104). The planned duration of treatment was specified to be between
14 and 72 days, depending on the timing of surgery. Patients were deemed not evaluable for
the primary endpoint if the length of BR-DIM
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treatment duration was outside the protocoldefined 14-72 day pre-prostatectomy window.
A change in surgery date caused the duration
of BR-DIM treatment to fall outside of the 14-72
day window for five patients. Prostatectomy
was cancelled for one patient because of adhesions found at the time of surgery. Treatment
duration was less than 14 days for two patients who withdrew from the study, and for one
patient who discontinued therapy because of
toxicity. Three patients did not have evaluable
clinical samples for biomarker analyses on the
day of prostatectomy. In summary, a total of 28
patients were evaluable for the primary endpoint of DIM levels in the prostate (Figure 1).
In addition to duration of treatment with BRDIM, compliance was assessed to ensure adequate BR-DIM exposure. Compliance was measured with pill diaries and by comparing actual
to expected returned pill counts. Median compliance by patient diary was 100% of intended
BR-DIM treatment for all registered patients
(range 0-100%). In the subset of 28 evaluable
patients, compliance by patient diary ranged
from 96-100% of intended treatment, rendering all evaluable patients compliant with therapy. Median compliance as measured by pill
count was 95% for all 37 patients who were
dispensed BR-DIM tablets (range 0-217%). In
the 28 evaluable patients, compliance by pill

Am J Transl Res 2016;8(1):166-176
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Table 2. Pre- and post-treatment measures among the 28 evaluable patients
Characteristic

N Median Mean

Plasma PSA pre-treatment (ng/mL)
Plasma PSA post-treatment (ng/mL)
Plasma PSA difference (ng/mL)
Plasma DIM pre-treatment (ng/mL)
Plasma DIM post-treatment (ng/mL)
Prostate tissue DIM post-treatment (ng/gm)

28
23
23
27
28
28

6.4
5.9
-0.6
0.0
7.5
11.6

7.2
6.8
-1.0
0.0
9.0
14.2

90% confidence limits
Lower
Upper
5.8
8.6
5.5
8.1
-2.0
0.0
0.0
0.0
6.8
11.3
10.6
17.7

SDa Minimum Maximum
4.3
3.6
2.7
0.0
6.9
11.1

50.0
2.6
-8.1
0.0
0.0
0.0

73.0
18.0
5.3
0.0
24.7
50.1

Standard deviation.

a

Pharmacokinetic and pharmacodynamic measures

Figure 2. Prostatic DIM measurements. A. After a minimum of 14 days of
BR-DIM therapy, DIM levels were measured in the plasma and at the time
of prostatectomy. Prostate DIM levels are plotted against plasma DIM
levels for each evaluable patient. The nonparametric regression LOESS
curve is plotted, with the shaded area indicating the 90% confidence
limits for the predicted mean prostate tissue DIM level. B. Prostate DIM
levels are plotted against length of BR-DIM treatment for each evaluable
patient. The nonparametric regression LOESS curve is plotted, with the
shaded area indicating the 90% confidence limits for the predicted mean
prostate tissue DIM level.

count ranged from 80-217% of intended treatment, with a median value of 96%.
171

Pre- and post-treatment pharmacokinetic and pharmacodynamic
measures are summarized in
Table 2. Plasma DIM levels were
measured for each patient prior
to starting to BR-DIM therapy. No
patient had detectable DIM levels in the pre-treatment sample.
Post-treatment DIM levels were
taken on the morning of surgery,
approximately twelve hours after
the last dose of BR-DIM. Posttreatment DIM levels were available for all evaluable patients.
Plasma DIM levels were detectable after BR-DIM therapy in all
but one patient. For evaluable
patients, the median plasma DIM
level in the post-treatment sample was 7.5 ng/mL (range 0-24.7
ng/mL). The mean plasma DIM
level on BR-DIM therapy was 9.0
ng/mL (90% CI: 6.8-11.3 ng/mL).
Plasma DIM levels were again
measured during follow-up, typically at least one month after surgery. Levels of DIM in the plasma
were undetectable at this timepoint for the subset of patients
with available data (n=8).

To assess our primary endpoint,
DIM levels were measured in the
prostate using a freshly frozen
prostate sample taken at the
time of surgery. Prostatic DIM
levels were available for all 28
evaluable patients. DIM levels
were detectable in the prostate for 26 of 28
patients (92.9%). The median DIM level in the
Am J Transl Res 2016;8(1):166-176
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Figure 3. BR-DIM therapy results in nuclear exclusion of androgen receptor. Prostate specimens were stained for androgen receptor. Representative images from samples taken before (A) and after (B) BR-DIM treatment are shown at
40X magnification. Vacuoles in the post-BR-DIM treatment group are indicative of nuclear exclusion of the androgen
receptor. AR staining score and the percentage of cases with nuclear staining of androgen receptor before and after
BR-DIM therapy are plotted in (C) and (D), respectively.

prostate was 11.6 ng/g and the mean DIM concentration was 14.2 ng/g (90% CI: 10.6-17.7
ng/g). Prostatic DIM levels did not correlate
strongly with plasma DIM levels (Spearman
rank correlation coefficient 0.53; 90% CI: 0.240.72). The nonparametric regression LOESS
curve of prostatic DIM levels was increasing
through about 12 ng/mL of plasma DIM, but
flat thereafter (Figure 2A). There was virtually
no relationship between prostatic DIM levels
and length of therapy (Spearman rank correlation coefficient -0.08; 90% CI: -0.39-0.24), consistent with our previous demonstration that
systemic steady state levels are achieved after
one week of BR-DIM therapy [19]. The nonparametric regression LOESS curve of prostatic DIM
levels was essentially flat through about 30
days of BR-DIM treatment, and slightly decreasing thereafter (Figure 2B). The mean (median)
prostatic DIM levels for the six patients who
took only the minimum amount of BR-DIM ther172

apy (14 days) was 14.0 (10.1) ng/gm, compared to a mean level of 14.2 (13.6) ng/gm for
the 22 patients who took BR-DIM therapy for >
14 days (see also Figure 2B).
BR-DIM effects on in vivo androgen receptor
signaling
Given the effects of DIM on the androgen receptor in pre-clinical models, we assessed androgen receptor staining in prostate samples
before and after BR-DIM treatment. Pre-BRDIM AR staining was performed on pre-therapy
biopsy specimens while post-BR-DIM AR staining was performed on specimens taken at the
time of prostatectomy. Androgen receptor status was unknown for 2 patients, yielding 26
patients evaluable for these analyses. A score
was assigned to each prostate sample equal to
the product of staining intensity and percent
positively-stained cells. The median AR staining
Am J Transl Res 2016;8(1):166-176
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revealed nuclear exclusion
in 25 of 26 prostatectomy
specimens (Figure 3). One
prostatectomy sample (4%;
90% CI: 1%-16%) showed nuclear androgen receptor staining. Androgen receptor staining was also performed
on archived prostate biopsy
samples obtained from the
patient prior to starting BRDIM therapy. These pre-BRDIM prostate biopsy samples did not demonstrate nuclear exclusion of androgen
receptor for any of the 26
evaluable patients, hence a
nuclear androgen receptor
staining rate of 100% (90%
CI: 91%-100%) (Figure 3). Compared to pre-BR-DIM samples, post-BR-DIM prostate
cancer samples demonstrated a striking effect on AR
nuclear translocation.
Nuclear translocation of androgen receptor is expected
in the presence of its ligand,
testosterone. We therefore
evaluated testosterone levels before and after BR-DIM
treatment. Nuclear exclusion of androgen receptor was
not dependent upon reduced circulating levels of testosterone. The median plasFigure 4. Waterfall plots of PSA declines. PSA declines are presented in waterma testosterone level after
fall format for both absolute (A) and % PSA declines (B).
BR-DIM treatment was 387
ng/mL (range 118-686). In
comparison, the median plasma testosterone
score in the 26 pre-BR-DIM specimens was
level prior to BR-DIM treatment was 280 ng/mL
300 while the median AR staining score in the
(range 77-557 ng/mL). In the 26 patients evalusame 26 post-BR-DIM prostatectomy samples
able for androgen receptor staining, plasma
was 255. The mean AR staining in the pre-BRtestosterone levels increased post-BR-DIM thDIM specimens was 278 (90% CI: 263-293)
erapy in 15 patients, decreased in six patients
compared to a mean value of 245 (90% CI: 227and were unknown in five patients. The mean
263) in the post-BR-DIM specimens. Staining
difference between pre- and post-BR-DIM tesscores suggested decreased protein exprestosterone levels was an increase of 76 ng/mL
sion of the androgen receptor in response to
(range -107 ng/mL to 359 ng/mL).
therapy.
As a nuclear receptor and transcriptional coactivator, translocation of the androgen receptor
to the nucleus after ligand binding is an important measure of its biologic activity. Immunohistochemical staining for androgen receptor
173

In addition to its clinical utility as a tumor marker, prostate-specific antigen (PSA) is an important target of AR-dependent transcription. PSA
levels were assessed both before and after
therapy with BR-DIM (Table 2). PSA levels
Am J Transl Res 2016;8(1):166-176
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Table 3. Adverse Event rates among all 36 treated patients
Adverse Event

N (%)

Headache
Gastrointestinal toxicity
Hematologic toxicity
Hyperglycemia
Hyponatremia
Increased creatinine
Increase in coagulation parameters

2 (6%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)

90% confidence limits Grade
Lower Upper
2%
15%
3
0%
7%
N/A
0%
7%
N/A
0%
7%
N/A
0%
7%
N/A
0%
7%
N/A
0%
7%
N/A

N/A = Not applicable.

declined in 16 of 23 patients (70%). In 28
patients, the median PSA level prior to therapy
was 6.4 ng/mL (range 2.1 ng/mL to 20.5 ng/
mL). In 23 patients, the median PSA level after
BR-DIM treatment was 5.9 ng/mL (range 2.6
ng/mL to 18.0 ng/mL). The median change in
absolute PSA levels of 23 patients was a 0.6
ng/mL decline (range 8.1 ng/mL decline to 5.3
ng/mL increase). PSA changes after BR-DIM
therapy are presented in waterfall plots (Figure
4).
Adverse events
Patients were deemed evaluable for toxicity
from their first dose of BR-DIM. Laboratory
monitoring included glucose, creatinine, sodium, liver function testing and coagulation parameters given previous reports of asymptomatic laboratory abnormalities in patients treated with BR-DIM [19]. Overall, BR-DIM was very
well tolerated. Two patients reported headaches (maximal CTCAE grade 3) which were deemed by the investigator to be possibly related
to BR-DIM therapy. No other toxicity was reported (Table 3).
Discussion
Overall, our results indicate that treatment with
BR-DIM is associated with biologically significant DIM concentrations in the human prostate. After BR-DIM treatment (225 mg orally
twice daily), we found that prostatic DIM levels
are reliably detected by fourteen days, and levels do not increase with longer treatment. These findings are consistent with our previous
reports that steady state levels in the plasma
are achieved by one week [19]. DIM was not
detectable in the plasma in any of 8 follow-up
samples. Toxicity from BR-DIM appears to be
174

minimal, with headache the only reported side effect.

Prostatic DIM may result in decreased expression of AR as assessed
by immunohistochemical staining,
but more prominent was the near
universal presence of nuclear vacuoles indicating AR nuclear exclusion.
Inhibition of nuclear translocation
has also been reported for other
novel anti-androgens such as enzalutamide and may contribute to the
anti-neoplastic activity of this class
of drug. AR nuclear exclusion was
observed even in the presence of ligand, as
serum testosterone levels generally were higher after BR-DIM therapy. The inability of AR to
translocate to the nucleus would be expected
to impact its ability to direct transcription in
response to ligand signaling. We observed decreases in serum PSA in a majority of patients,
consistent with a potential effect on AR signaling. Although observed decreases were small,
treatment duration was quite short (median of
19 days) and the study was not designed to
assess changes in PSA as its primary endpoint.
Clinical guidelines suggest continuing treatment for at least 12 weeks to ensure adequate
drug exposure when evaluating changes in PSA
[21].
Attrition rate on this study was higher than
anticipated from our previous experience in the
setting of castrate-resistant biochemical recurrence, potentially related to the studied surgical patient population. In contrast to patients
experiencing cancer recurrence, prostatectomy
patients being treated with curative intent may
be less tolerant of toxicity or inconvenience
from an experimental therapy, even if mild.
Furthermore, several patients were not evaluable because patients chose to change surgical dates rather than continue on study. Although attrition is a study limitation, adequate
numbers of patients were enrolled to evaluate
our primary endpoint according to the original
statistical plan.
In summary, treatment with BR-DIM was successful in maintaining biologically active levels
of DIM in the prostate. BR-DIM clearly impacts
nuclear translocation of the androgen receptor,
which plays a key role in prostate tumor pathogenesis. Confirming the anti-androgenic activity
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of BR-DIM in humans supports the further
study of this nutraceutical as both a therapeutic and chemopreventive agent.
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